India plans to include the Serum Institute of India's Cervavac HPV vaccine in the National Immunisation Programme after 2027, pending successful single-dose clinical trial results. The move aims to expand cervical cancer prevention, improve vaccine coverage among adolescent girls, reduce healthcare costs, and strengthen the country's long-term public health strategy.